EGFR and lung carcinoma: For instance, deletion of four highly conserved amino acids, LREA, in EGFR exon 19 and the L858R point mutation in exon 21 of lung cancer improves therapeutic response to EGFR-TKIs.15,16 (II) Genomic amplification and overexpression is the second major type of mutation.